Gadovist®: the only 1.0 M gadolinium based contrast agent (GBCA)1

Gadovist is a macrocyclic, extracellular GBCA that can be used for MR Imaging of the whole body for all ages2

Gadovist is used for visualisation and diagnosis of pathological lesions, and for evaluation of perfusion and blood flow2

Click here for Gadovist prescribing information

Access to prescribing information and adverse event reporting can be found at the bottom of the page



Gadovist is indicated in adults and children of all ages (including term neonates) for:

  • Contrast enhancement in cranial and spinal MRI
  • Contrast enhancement MRI of liver or kidneys in patients with high suspicion or evidence of having focal lesion to classify these lesions as benign or malignant
  • Contrast enhancement in MRA

Gadovist can also be used for MRI of pathologies of the whole body; it facilitates visualisation of abnormal structures or lesions, and helps in the differentiation between healthy and pathological tissue

Contrast enhancement in five key specialised areas3

  • Cardiology
  • CNS
  • MRA and CNS perfusion imaging
  • Oncology
  • Paediatrics

The benefits of Gadovist®

Gadovist: high signal intensity4 and excellent contrast enhancement through rating by healthcare professionals3,5

Due to its 1.0 M concentration2 and high relaxivity4, Gadovist has a higher T1-shortening effect per milliliter than other GBCAs4,6

  • The injection volume is half that of 0.5 M GBCAs, therefore administration takes half the time8
  • A range of vials and pre-filled syringes allow flexible dosing and administration
  • In a study of more than 23,000 patients, 0.9% reported 251 adverse events (AE). For these AEs, 0.7% were categorized as adverse drug reactions (ADR), the intensity of ADRs were 84.9% mild, 12.0% moderate and 2.4% severe3
Relative T1 shortening times


T1-shortening times of Gadovist and other GBCAs with 1mL/L volume concentration of contrast media.

*From 01 February 2018, the licences for Omniscan and Magnevist IV 0.5mmol have been suspended, and the license for MultiHance has been amended for use in liver imaging only; following the European Medical Agency (EMA) European Commission Article 31 Referral, Gadolinium Presence in the Brain.

Adapted from reference 6

Calculated for blood at 1.5 T using T10 = 1,200 ms

Get in Touch to Learn More


  1. Bellin MF. and Van Der Molen AJ. Eur J Radiol 2008;66(2):160-167.
  2. Gadovist Summary of Product Characteristics. August 2020.
  3. Prince MR et al. Eur Radiol 2017;10.1007/s00330-016-4268-8.
  4. Rohrer M et al. Invest Radiol 2005;40(11):715-724.
  5. Glutig K et al. Pediatr Radiol 2016;46(9):1317-1323.
  6. Bayer Data on File. T1 Shortening Calculation. October 2019.
  7. Endrikat J et al. Invest Radiol 2016;51:537-543.
  8. Reiser M et al. Magnetic Resonance Tomography. Springer-Verlag Berlin Heidelberg; 2008, pp 98-99.